Interestingly, Vps34 inhibitors (e.g. alpelisib and buparlisib) are promising anti-cancer drugs currently in clinical trials (Castel et al., 2021); thus, our results indicate synergy with MTDIA could be an effective dual therapy. Here, PIK3C3 is linked to cancer.